One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Imposter clinical trials or answering questions with observational data
Gary Cutter
doi : 10.1177/13524585231162261
Volume 29 Issue 6, May 2023
T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy
Anthony T Reder, Olaf Stuve , Stephanie K Tankou and Thomas P Leist
doi : 10.1177/13524585221134216
Multiple sclerosis (MS) is a neurological disorder marked by accumulating immune-mediated damage to the central nervous system. The dysregulated immune system in MS combined with immune effects of disease-modifying therapies (DMTs) used in MS treatment could alter responses to infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).
Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis
Yew Li Dang* , Vivien TY Yong*, Sifat Sharmin, Piero Perucca and Tomas Kalincik
doi : 10.1177/13524585231151400
Multiple sclerosis patients experience 3–6 times more seizures than the general population, but observations vary among studies. Seizure risk in disease-modifying therapy recipients remains unknown.
The contribution of neurofilament light chain to better characterize pediatric multiple sclerosis (editorial on: Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial)
Angelo Ghezzi and Rinze F Neuteboom
Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study
Raffaele Palladino, Ruth Ann Marrie , Azeem Majeed and Jeremy Chataway
doi : 10.1177/13524585231164296
Vascular management in People with Multiple Sclerosis (PwMS) is important given the higher vascular burden than the general population, associated with increased disability and mortality.
Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis
Colm Elliott , David A Rudko, Douglas L Arnold , Dumitru Fetco, Ahmed M Elkady, David Araujo, Bing Zhu , Arie Gafson, Zhe Tian, Shibeshih Belachew, Daniel P Bradley and Elizabeth Fisher
doi : 10.1177/13524585231162262
Paramagnetic rim lesions (PRLs) and slowly expanding lesions (SELs) have been posited as markers of chronic active lesions (CALs).
Selective vulnerability of brainstem and cervical spinal cord regions in people with non-progressive multiple sclerosis of Black or African American and European ancestry
Darin T Okuda , Thomas Stanley, Morgan McCreary , Alexander Smith, Andrew Wilson, Marco C Pinho, Fang F Yu, Thibo Billiet , Wim Van Hecke, Annemie Ribbens, Burcu Zeydan , Orhun Kantarci, Xiaohu Guo and Tatum M Moog
doi : 10.1177/13524585221139575
We evaluated imaging features suggestive of neurodegeneration within the brainstem and upper cervical spinal cord (UCSC) in non-progressive multiple sclerosis (MS).
Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis
Charidimos Tsagkas, Antal Huck-Horvath, Alessandro Cagol , Tanja Haas, Muhamed Barakovic, Michael Amann, Esther Ruberte, Lester Melie-Garcia, Matthias Weigel, Simon Pezold, Regina Schlaeger, Jens Kuhle, Till Sprenger, Ludwig Kappos , Oliver Bieri, Philippe Cattin, Cristina Granziera and Katrin Parmar
doi : 10.1177/13524585221139152
Spinal cord (SC) gray and white matter pathology plays a central role in multiple sclerosis (MS).
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study
Gavin Giovannoni, Alexey Boyko, Jorge Correale, Gilles Edan, Mark S Freedman, Xavier Montalban, Kottil Rammohan, Dusan Stefoski, Bassem Yamout, Thomas Leist, Aida Aydemir, Laszlo Borsi and Elisabetta Verdun di Cantogno
doi : 10.1177/13524585231161494
CLASSIC-MS evaluated the long-term efficacy of cladribine tablets in patients with relapsing multiple sclerosis.
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
Katharina Fink, Agnes Gorczyca, Peter Alping , Simon Englund , Susan Farmand, Annette M Langer-Gould , Fredrik Piehl , Kyla McKay, Thomas Frisell and Neda Razaz
doi : 10.1177/13524585231161492
There is a paucity of information on maternal multiple sclerosis (MS) and risk of adverse pregnancy and perinatal outcomes.
Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging
Shannon Kolind, Laura Gaetano , Haz-Edine Assemlal, Corrado Bernasconi, Ulrike Bonati, Colm Elliott , Niels Hagenbuch, Stefano Magon, Douglas L Arnold* and Anthony Traboulsee
doi : 10.1177/13524585231162586
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by two major and interconnected hallmarks: inflammation and progressive neurodegeneration.
Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis
Nicholas H Chia , Vyanka Redenbaugh , John J Chen, Sean J Pittock and Eoin P Flanagan
doi : 10.1177/13524585221150743
Data on corpus callosum involvement in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are limited.
Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC)
Dejan Jakimovski , Katelyn S Kavak, Karen Zakalik, Timothy Coetzee , Malcolm Gottesman, Patricia K Coyle, Robert Zivadinov and Bianca Weinstock-Guttman on behalf of New York State Multiple Sclerosis Consortium (NYSMSC)
doi : 10.1177/13524585221140271
Judicious multiple sclerosis (MS) diagnosis and early start of disease modifying therapy significantly improves long-term disability outcomes in persons with MS (pwMS).
Humoral COVID-19 vaccine response in patients with NMOSD/MOGAD during anti-IL-6 receptor therapy compared to other immunotherapies
Carolin Schwake , Thivya Pakeerathan, Ingo Kleiter, Marius Ringelstein, Orhan Aktas, Mirjam Korporal-Kuhnke, Brigitte Wildemann, Sven Jarius, Antonios Bayas, Refik Pul, Ulas Ceylan, Simon Faissner, Kerstin Hellwig, Ana Beatriz Ayroza Galvao Ribeiro Gomes, Philipp Lipps, Anne-Katrin Pröbstel, Tania Kümpfel, Eva Oswald, Florian Then Bergh, Clemens Gödel, Martin W Hümmert , Corinna Trebst, Ralf Gold and Ilya Ayzenberg
doi : 10.1177/13524585221151124
Data on the humoral vaccine response in patients on anti-interleukin-6 (IL-6) receptor therapy remain scarce.
Olfactory threshold as a biomarker of disease activity
Mónica Santos1,2, Ruth Geraldes2,3 and Jacqueline Palace
Reply to letter to the editor: Olfactory threshold as a biomarker of disease activity
Gabriel BstehThomas Berger
A spoonful of sugar: The risks of negative health outcomes of polypharmacy in MS is a bitter reality
Sharon Roman
